

The Critical Role of Pediatric Clinicians in Achieving Best Practices in Atopic Dermatitis Assessment, Management, and Referral



Monday, November 8, 2021

6:00 PM – 7:30 PM ET

Maryland Chapter of the AAP Virtual Webinar

Register here: www.integrityce.com/MDAAP-Reg

Faculty Presenter



Elaine Siegfried, MD

Professor of Pediatrics and Dermatology
Department of Pediatrics
Saint Louis University
St. Louis, Missouri

Program Overview

Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that affects 7.2% of adults and 12% of children. Disability and a poor quality of life (QOL) are associated with AD, particularly among patients who are suboptimally managed. Pediatricians and primary care providers (PCPs) are often the first point-of-contact for patients with AD. Data from 1996-1999 compared to 2012-2015 found that PCP visits for children and adults with AD increased 300%, yet dermatologist visits for AD decreased 17%. In children, pediatricians were the most frequently sought provider for AD.

Although PCPs and pediatricians are seeing an increase in AD cases, recent evidence shows these clinicians are lacking in their ability to accurately diagnose and assess disease severity. In a recent survey, only 29% of PCPs were able to recognize essential features and characteristic distribution of AD to support diagnosis. Another survey found a discrepancy between how physicians and patients rate AD severity, with patients focusing more on skin-related QOL outcomes and physicians focusing more on sleep disturbance. In pooled data from prior Integrity CE programs on AD targeting PCPs and pediatricians, only 46% of participants selected to assess itch, sleep, and daily life vs objective measures to determine AD severity at baseline. Early-onset AD, which develops within the first 2 years of life, occurs in 60% of children with AD. While as many as 2 out of 3 of these children will experience remission before age 11, recurrences in adolescence and early adulthood are common. Many moderate-to-severe cases of AD in adulthood often begin as early-onset disease that was suboptimally treated or miscategorized. Education to ensure clinicians are prepared to effectively diagnose and assess disease severity is therefore necessary. This series will address these educational gaps among PCPs and pediatricians, and application of the knowledge gained will improve outcomes for patients with AD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

- Integrate evidence-based diagnostic criteria and assessment strategies into the routine identification and evaluation of children and adults with known or suspected AD
- Apply current guideline recommendations to the effective management of children and adults with AD
- Review safety and efficacy data on new and emerging therapies for children and adults with AD
- Demonstrate prompt referral of patients with AD to specialist care in accordance with guideline recommendations and best practices

Format

This program will provide a case-based presentation featuring slides and interactive case studies. A question-and-answer session hosted by the faculty presenter will follow at the conclusion of the presentation.



Provided by Integrity Continuing Education, Inc.

This activity is supported by an independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.



Accreditation

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this live activity for a maximum of **1.5 AMA PRA Category 1 Credit(s)TM**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to receive credit

In order to receive credit for this activity, the participant must complete the posttest and evaluation form in its entirety. Once submitted, it will be processed and you will receive your certificate within four weeks.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Elaine Siegfried, MD

Consultant Fees: AbbVie, ASLAN Pharmaceuticals, Boehringer Ingelheim, Incyte, Leo, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi Genzyme, UCB, Verrica

Contracted Research: AI Therapeutics

DSMB: Leo, Novan, Pfizer, UCB

Fees to SSM/SLY related to clinical trial: Janssen, Lilly, Pfizer, Pierre Fabre, Regeneron, Verrica

Grant funding to support 2020-2022 Peds Derm Fellow: Pfizer

Honoraria: Regeneron, Sanofi Genzyme, Verrica

PI: Janssen

Integrity CE has nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. or Sanofi Genzyme and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com